by E Kornelius 2024 Cited by 5Patients with DPP4i prescriptions were selected as cases, while non-DPP4i users served as controls. Am J Cardiovasc Drugs. 2024; 13: . View in
by JE Gunton Cited by 4Most drugs (including metformin, sulfonylureas, acarbose, some DPP4i, TZD and insulin) do not need to be discontinued in patients with mild to
Consider adding SGLT2i if as above but ACR 3-30. Step 3. If HbA1c≥ . Add further oral drugs from choice of sulfonylurea, pioglitazone, DPP4i (
Patients taking dipeptidyl peptidase4 drugs (DPP4i)a Type 2 diabetes drughad an incidence of acute pancreatitis recurrence of 23.3% versus
Finally, 111 participants treated with DPP4i drugs were successfully matched to 333 non-DPP4i users. Then, a linear logistic model and mixed-effect Cox
by M Zhao 2024 Cited by 51DPP4i is a class of new drugs that treat type 2 diabetes effectively. The advantages of using DPP4i for diabetes therapy are their
Add further oral drugs from choice of sulfonylurea, pioglitazone, DPP4i (gliptin) or SGLT2i. GLP-1. If HbA1c≥ . If BMI 35, consider replacing one of three
Patients taking DPP4i drugs were older and had a lower body mass index (BMI) compared to GLP1-RA or SGLT2i users. Patients in the DPP4i
by S Ray 2024Among DPP4i, Sitagliptin improved 24-h glycemic fluctuation and reduced postprandial hyperglycemia. Antidiabetic drugs like DPP4is improve glycemic
Comments